Servier is a European research based pharmaceutical company focusing on the areas of oncology, cardiovascular and Central Nervous System diseases.
Established in 1954 by Dr Jacques Servier, the company launched its first products targeting hypertension and diabetes within one year of opening. By 1960 the company’s first research centre had been set up and this is where the company’s hunger for research truly began. Today the company owns the largest research unit in Europe known as the Clinical Support Unit which produces drugs direct from clinical trials.
Servier’s strategy is to focus on early stage compounds and it is evident through the research collaborations it has made that this forms a key part of its core business model. Servier has signed over 50 deals over the last 8 years with most of them based around compounds at the discovery stage of development. The company nurtures innovations from the very start and prefers to do it this way rather than acquire aspiring treatments from other companies.
Over the years Servier has chosen not to merge or acquire with any companies which is a very different business approach to that of the main big pharmaceutical companies; there is no recent history of any M&A activity between this company and any others. Most of Servier’s deals are collaborative R&D deals or licensing deals and this reflects their mission to work and research on as many in-house compounds as possible.
It is well known that Servier re-invests a lot of its revenue back into research; 25% is the actual figure. This ensures that new compounds are supported and successfully grown to make sure they reach the desired stage without the research or monetary help from any other companies.
Summary of Partnering Interests
Servier is committed to developing medications for the treatment of oncology, rheumatology and metabolic conditions. Some of its key products include Glicalazide (antidiabetic drug), Indapamide (diuretic) and Trimetazidine (angina). The company also has products for venous disease, depression and menopause. Recent key products in the following therapeutic areas have been noted:
- Oncology – Melanoma
- Cardiovascular – Angina, blood pressure, heart disease, hypertension
- Metabolic – Diabetes,
- Rheumatology – Osteoporosis
- Central Nervous System – Depression
Servier is routinely present at a large number of partnering events throughout the year.
Partnering events are a great place to meet lots of potential partners face to face in a small amount of time.
Events with Servier presence include but are not limited to:
- BIO International Convention and Business Forum
- BioEurope / BioEurope Spring
For a full list of forthcoming partnering events where you could meet with Servier in person visit Current Partnering’s Event calendar.
Contacting Servier for partnering
Servier can be contacting in relation to partnering through a number of channels.
Here is a list of the most common channels:
Partnering events: face to face contact is generally considered the most effective form of contact. Partnering events not only allow face to face contact but also contact with multiple companies for the price of one flight and hotel reservation. This benefit makes partnering events the most cost effective method of making personal introductions as a start point for partnering discussions.
See Current Partnering’s event calendar for details of forthcoming events.
Direct contact: there are several sources of direct contact with Servier’s business development team
- Phone: Picking up the phone and speaking with an individual is the best form of non-face to face contact as it allows your name and voice to be remembered and associated with an opportunity.
- Email: Sending an email is another good way of making contact. Ideally, research the individual responsible for the therapy/technology area being targeted and get in touch. Email contact to a named individual view the list of contacts at Servier’s website for details.
- LinkedIn: Business to business contact is increasingly taking place via LinkedIn, the global online networking channel. Many of Servier’s business development executives have LinkedIn profiles and can be found by viewing the company’s profile. Visit Servier’s LinkedIn page here.
Opportunity submission form: the least favourable channel but worth using if you do not have access to the other channels mentioned above. Servier does not provide an online opportunity submission form.
No M&A activity recorded for Servier
Available reports from Current Partnering
Report: Partnering Deals and Alliances with Servier
Available resources for deal coverage for Servier
Read: more on Servier company profile, recent partnering, M&A and financing news and articles
Report: Practical Guide to Finding Partners
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk